Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. THIS QUARTER, WE CONTINUED TO EXECUTE ACROSS A DIVERSE PIPELINE SPANNING MULTIPLE, POTENTIALLY HIGH IMPACT PROJECTS IN INFECTIOUS DISEASES AND ONCOLOGY, LEVERAGING OUR BORON CHEMISTRY PLATFORM TO AD.

AN2 THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY ADVANCING NOVEL SMALL MOLECULE THERAPEUTICS THROUGH ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED A COLLABORATION AGREEMENT WITH THE GLOBAL BIOPHARMA COMPANY GSK TO DEVELOP NEW THERAPIES FOR TUBERCULOSIS (TB). AS PART OF THIS EFFORT, THE GATES FOUNDATION WILL PROVIDE A THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN THE COLLABORATION. TB CONTINUES TO POSE A MAJOR GLOBAL HEALTH CHALLENGE, A.

AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND CEO, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 8TH ANNUAL EVERCORE HEALTHCONX CONFERENCE BEING HELD FROM DECEMBER 2-4, 2025. DETAILS OF THE EVENT ARE AS FOLLOWS: ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND.

AN2 Therapeutics, Inc.

ANTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AN2 Therapeutics, Inc.

ANTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ANTX